GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.Aquestive Faces Class Action Over Anaphylm FDA Approval Misstatements
Aquestive Therapeutics faces class action lawsuit alleging FDA approval misrepresentations for Anaphylm. Stock dropped 37% January 9; lead plaintiff applications due May 4, 2026.
AQSTsecurities fraudclass action lawsuit